Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Prostatic Neoplasms × Adrenal Cortex Hormones × Clear all

Phase

Phase 2 3 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Brain Neoplasms 2 Radiation Injuries 1 Prostatic Neoplasms 1 Popliteal Cyst 1 Pneumonia 1 Optic Neuritis 1 Myelitis, Transverse 1 Myelitis 1 Myasthenia Gravis 1 Glioma 1 Breast Neoplasms 1 Arthritis, Rheumatoid 1

Interventions

Prednisone 45 Docetaxel 44 Radiotherapy 41 Goserelin 39 Leuprolide 38 bicalutamide 35 enzalutamide 26 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 24 Androgen Antagonists 22 Flutamide 19 Triptorelin Pamoate 17 apalutamide 16 Zoledronic Acid 13 Gonadotropin-Releasing Hormone 12 Abiraterone Acetate 12 gallium 68 PSMA-11 11 abiraterone 11 Radiation 11 Magnetic Resonance Spectroscopy 11 Prednisolone 9 Estramustine 8 Dexamethasone 8 cabazitaxel 7 Specimen Handling 7 Mitoxantrone 7 Chemotherapy, Adjuvant 7 Buserelin 7 orteronel 6 luprolide acetate gel depot 6 darolutamide 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06925737 2026-03-13

MK-2400-001

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡